|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
Objectives To assess whether risedronate can slow the progression of joint space narrowing (JSN) (as measured radiographically in the medial compartment of the tibiofemoral joint) in the signal knee of patients with mild-to-moderate primary OA relative to placebo-treated patients.
To evaluate the effect of risedronate on pain, stiffness, functional status, patient's global assessment of his/her disease, osteophyte area on the medial and lateral tibial edges in the signal knee and use of pain medication for osteoarthritis. Inclusion Criteria Women or men, 40-80 years old
Normal TSH at screen, if on thyroid therapy
At least one knee with osteoarthritis, pain on most days during at least 1 month out of the past 3 months
At least one osteophyte
Must meet criteria as determined by central x-ray facility
Able to complete patient questionnaires Exclusion Criteria Conditions causing secondary knee OA
Untreated hyperparathyroidism
Untreated hyperthyroidism
Intra-articular injection of Corticosteroid into either knee within 3 months
Intra-articular injection of Hyaluronic Acid (Synvisc, Hyalagan) within 6 months
Knee surgery
Cancer within 10 years (except squamous or basal cell carcinoma, or cervical carcinoma in situ)
Non-OA causes of knee pain
Diagnostic arthroscopy without surgical procedure within 6 months
Injury to signal knee within 6 months requiring a MD visit
Major surgery requiring inpatient hospitalization within 1 month of screening
Treatment with tetracyclines within 6 months
Calcitonin or fluoride within 6 months
Use of bisphosphonates within 12 months
Corticosteroid use (>5mg/day Prednisone) within 3 months CONTACT: |
|
|
|
|
|
 |
||||
Home | General Information | Departments | Programs info@hjdhospital.comemploymentopportunities@hjdhospital.com Contact the webmaster@msnyuhealth.org with your comments. Copyright © 2000-2003 Mount Sinai NYU Health
|
||||